论文部分内容阅读
目的探讨拉米夫定联合干扰素α治疗慢性乙型病毒肝炎的临床疗效。方法将93例患者分成2组,拉米夫定组58例,干扰素组35例;疗程1年,分别于治疗1、2、6个月和12个月时复查ALT、HBV-DNA及乙肝病毒血清标志物(乙肝五项)。结果 2组各观察时间段ALT正常率比较、HBV-DNA转阴率比较,差异均无显著统计学意义(P>0.05)。干扰素组HBeAg转阴率优于拉米夫定组,差异具有非常显著统计学意义(P<0.001);干扰索组HBsAg转阴率亦优于拉米夫定组,差异具有显著统计学意义(P<0.05)。结论观察显示,干扰素类药物HBeAg、HBsAg转阴率相对较拉米夫定高。故对无应用禁忌者,推荐此药为年轻代偿期慢性乙肝患者抗病毒治疗的首选用药。
Objective To investigate the clinical efficacy of lamivudine in combination with interferon α in the treatment of chronic hepatitis B virus. Methods Ninety-three patients were divided into two groups: lamivudine group (58 cases) and interferon group (35 cases). The duration of treatment was 1 year. ALT, HBV-DNA and hepatitis B Virus serum markers (hepatitis B five). Results There was no significant difference in the normal rate of ALT and the negative rate of HBV-DNA between the two groups in each observation time (P> 0.05). The negative rate of HBeAg in interferon group was better than that of lamivudine group (P <0.001), and the negative rate of HBsAg in interferon group was also better than that of lamivudine group, the difference was statistically significant (P <0.05). Conclusions The observation shows that the conversion rate of HBeAg and HBsAg of interferon is relatively higher than that of lamivudine. Therefore, no contraindications for use, recommend this drug for young compensated patients with chronic hepatitis B antiviral treatment of choice.